VERTEX PHARMACEUTICALS INC / MA Stock-Based Compensation
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Stock-Based Compensation of $336.60 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-04
- VERTEX PHARMACEUTICALS INC / MA share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $170.20M, a 1.73% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $166.40M, a 0.18% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $157.60M, a 6.08% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $194.90M, a 5.58% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA share-based payment arrangement, noncash expense for fiscal 2025 was $685.90M, a 1.80% decline from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA share-based payment arrangement, noncash expense for fiscal 2024 was $698.50M, a 20.18% increase from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA share-based payment arrangement, noncash expense for fiscal 2023 was $581.20M, a 18.30% increase from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA share-based payment arrangement, noncash expense for fiscal 2022 was $491.30M, a 11.30% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 6 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 9 month as first filed | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $170.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $336.60M 10-Q · filed 2026-08-04 | $494.20M derived: sum of 3 quarters · filed 2026-08-04 | $689.10M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $166.40M 10-Q · filed 2026-05-05 | $324.00M derived: sum of 2 quarters · filed 2026-05-05 | $518.90M derived: sum of 3 quarters · filed 2026-05-05 | $686.20M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $157.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $352.50M derived: sum of 2 quarters · filed 2026-02-13 | $519.80M derived: sum of 3 quarters · filed 2026-08-04 | $685.90M 10-K · filed 2026-02-13 | ||||
| 2025-09-30 | $194.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $362.20M derived: sum of 2 quarters · filed 2026-08-04 | $528.30M 10-Q · filed 2025-11-04 | $696.10M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $167.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $333.40M 10-Q · filed 2026-08-04 | $501.20M derived: sum of 3 quarters · filed 2026-08-04 | $685.80M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $166.10M 10-Q · filed 2026-05-05 | $333.90M derived: sum of 2 quarters · filed 2026-05-05 | $518.50M derived: sum of 3 quarters · filed 2026-05-05 | $672.70M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $167.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $352.40M derived: sum of 2 quarters · filed 2026-02-13 | $506.60M derived: sum of 3 quarters · filed 2026-02-13 | $698.50M 10-K · filed 2026-02-13 | ||||
| 2024-09-30 | $184.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $338.80M derived: sum of 2 quarters · filed 2025-11-04 | $530.70M 10-Q · filed 2025-11-04 | $739.30M derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2024-06-30 | $154.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $346.10M 10-Q · filed 2025-08-05 | $554.70M derived: sum of 3 quarters · filed 2026-02-13 | $685.60M derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2024-03-31 | $191.90M 10-Q · filed 2025-05-06 | $400.50M derived: sum of 2 quarters · filed 2026-02-13 | $531.40M derived: sum of 3 quarters · filed 2026-02-13 | $650.70M derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2023-12-31 | $208.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $339.50M derived: sum of 2 quarters · filed 2026-02-13 | $458.80M derived: sum of 3 quarters · filed 2026-02-13 | $581.20M 10-K · filed 2026-02-13 | ||||
| 2023-09-30 | $130.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $250.20M derived: sum of 2 quarters · filed 2024-11-05 | $372.60M 10-Q · filed 2024-11-05 | $484.10M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-06-30 | $119.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $241.70M 10-Q · filed 2024-08-02 | $353.20M derived: sum of 3 quarters · filed 2025-02-13 | $488.80M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-03-31 | $122.40M 10-Q · filed 2024-05-07 | $233.90M derived: sum of 2 quarters · filed 2025-02-13 | $369.50M derived: sum of 3 quarters · filed 2025-02-13 | $483.40M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2022-12-31 | $111.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $247.10M derived: sum of 2 quarters · filed 2025-02-13 | $361.00M derived: sum of 3 quarters · filed 2025-02-13 | $491.30M 10-K · filed 2025-02-13 | ||||
| 2022-09-30 | $135.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $249.50M derived: sum of 2 quarters · filed 2023-11-07 | $379.80M 10-Q · filed 2023-11-07 | $498.40M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-06-30 | $113.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $244.20M 10-Q · filed 2023-08-02 | $362.80M derived: sum of 3 quarters · filed 2024-02-15 | $465.80M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-03-31 | $130.30M 10-Q · filed 2023-05-02 | $248.90M derived: sum of 2 quarters · filed 2024-02-15 | $351.90M derived: sum of 3 quarters · filed 2024-02-15 | $456.50M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2021-12-31 | $118.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $221.60M derived: sum of 2 quarters · filed 2024-02-15 | $326.20M derived: sum of 3 quarters · filed 2024-02-15 | $441.40M 10-K · filed 2024-02-15 | ||||
| 2021-09-30 | $103.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-28 | $207.60M derived: sum of 2 quarters · filed 2022-10-28 | $322.80M 10-Q · filed 2022-10-28 | $322.79M 10-Q · filed 2021-11-03 | $419.87M derived: sum of 4 quarters · filed 2023-02-10 | |||
| 2021-06-30 | $104.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $219.80M 10-Q · filed 2022-08-05 | $219.80M 10-Q · filed 2021-07-30 | $316.87M derived: sum of 3 quarters · filed 2023-02-10 | $416.40M derived: sum of 4 quarters · filed 2023-02-10 | |||
| 2021-03-31 | $115.20M 10-Q · filed 2022-05-06 | $115.17M 10-Q · filed 2021-04-30 | $212.27M derived: sum of 2 quarters · filed 2023-02-10 | $311.81M derived: sum of 3 quarters · filed 2023-02-10 | $428.99M derived: sum of 4 quarters · filed 2023-02-10 | |||
| 2020-12-31 | $97.07M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10 | $196.60M derived: sum of 2 quarters · filed 2023-02-10 | $313.79M derived: sum of 3 quarters · filed 2023-02-10 | $429.50M 10-K · filed 2023-02-10 | $429.46M 10-K · filed 2021-02-11 | |||
| 2020-09-30 | $99.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $216.73M derived: sum of 2 quarters · filed 2021-11-03 | $332.43M 10-Q · filed 2021-11-03 | $424.04M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2020-06-30 | $117.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30 | $232.90M 10-Q · filed 2021-07-30 | $324.50M derived: sum of 3 quarters · filed 2022-02-09 | $409.92M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2020-03-31 | $115.71M 10-Q · filed 2021-04-30 | $207.31M derived: sum of 2 quarters · filed 2022-02-09 | $292.73M derived: sum of 3 quarters · filed 2022-02-09 | $382.42M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2019-12-31 | $91.60M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $177.02M derived: sum of 2 quarters · filed 2022-02-09 | $266.71M derived: sum of 3 quarters · filed 2022-02-09 | $360.50M 10-K · filed 2022-02-09 | $360.49M 10-K · filed 2020-02-13 | |||
| 2019-09-30 | $85.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $175.11M derived: sum of 2 quarters · filed 2020-10-30 | $268.90M 10-Q · filed 2020-10-30 | $347.84M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-06-30 | $89.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $183.48M 10-Q · filed 2020-07-31 | $262.42M derived: sum of 3 quarters · filed 2021-02-11 | $347.95M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-03-31 | $93.79M 10-Q · filed 2020-05-01 | $172.73M derived: sum of 2 quarters · filed 2021-02-11 | $258.27M derived: sum of 3 quarters · filed 2021-02-11 | $340.70M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2018-12-31 | $78.94M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $164.47M derived: sum of 2 quarters · filed 2021-02-11 | $246.91M derived: sum of 3 quarters · filed 2021-02-11 | $325.05M 10-K · filed 2021-02-11 | ||||
| 2018-09-30 | $85.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $167.97M derived: sum of 2 quarters · filed 2019-10-31 | $246.10M 10-Q · filed 2019-10-31 | $322.35M derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2018-06-30 | $82.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $160.57M 10-Q · filed 2019-08-01 | $236.82M derived: sum of 3 quarters · filed 2020-02-13 | $311.27M derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2018-03-31 | $78.14M 10-Q · filed 2019-05-01 | $154.38M derived: sum of 2 quarters · filed 2020-02-13 | $228.84M derived: sum of 3 quarters · filed 2020-02-13 | $301.93M derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2017-12-31 | $76.25M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $150.70M derived: sum of 2 quarters · filed 2020-02-13 | $223.80M derived: sum of 3 quarters · filed 2020-02-13 | $293.24M 10-K · filed 2020-02-13 | $290.74M 10-K · filed 2018-02-15 | |||
| 2017-09-30 | $74.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-25 | $147.55M derived: sum of 2 quarters · filed 2018-10-25 | $216.99M 10-Q · filed 2018-10-25 | $215.33M 10-Q · filed 2017-10-30 | $278.99M derived: sum of 4 quarters · filed 2019-02-13 | |||
| 2017-06-30 | $73.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26 | $142.53M 10-Q · filed 2018-07-26 | $141.56M 10-Q · filed 2017-07-28 | $204.53M derived: sum of 3 quarters · filed 2019-02-13 | $265.74M derived: sum of 4 quarters · filed 2019-02-13 | |||
| 2017-03-31 | $69.44M 10-Q · filed 2018-04-27 | $68.98M 10-Q · filed 2017-04-28 | $131.44M derived: sum of 2 quarters · filed 2019-02-13 | $192.65M derived: sum of 3 quarters · filed 2019-02-13 | $254.59M derived: sum of 4 quarters · filed 2019-02-13 | |||
| 2016-12-31 | $62.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | $123.21M derived: sum of 2 quarters · filed 2019-02-13 | $185.15M derived: sum of 3 quarters · filed 2019-02-13 | $240.62M 10-K · filed 2019-02-13 | $237.71M 10-K · filed 2017-02-23 | |||
| 2016-09-30 | $61.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-30 | $123.15M derived: sum of 2 quarters · filed 2017-10-30 | $178.62M 10-Q · filed 2017-10-30 | $223.27M derived: sum of 4 quarters · filed 2018-02-15 | ||||
| 2016-06-30 | $61.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | $117.41M 10-Q · filed 2017-07-28 | $162.06M derived: sum of 3 quarters · filed 2018-02-15 | $227.79M derived: sum of 4 quarters · filed 2018-02-15 | ||||
| 2016-03-31 | $55.47M 10-Q · filed 2017-04-28 | $100.12M derived: sum of 2 quarters · filed 2018-02-15 | $165.85M derived: sum of 3 quarters · filed 2018-02-15 | $229.11M derived: sum of 4 quarters · filed 2018-02-15 | ||||
| 2015-12-31 | $44.65M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $110.38M derived: sum of 2 quarters · filed 2018-02-15 | $173.64M derived: sum of 3 quarters · filed 2018-02-15 | $231.03M 10-K · filed 2018-02-15 | ||||
| 2015-09-30 | $65.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-31 | $129.00M derived: sum of 2 quarters · filed 2016-10-31 | $186.38M 10-Q · filed 2016-10-31 | $228.76M derived: sum of 4 quarters · filed 2017-02-23 | ||||
| 2015-06-30 | $63.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-01 | $120.64M 10-Q · filed 2016-08-01 | $163.03M derived: sum of 3 quarters · filed 2017-02-23 | $209.16M derived: sum of 4 quarters · filed 2017-02-23 | ||||
| 2015-03-31 | $57.38M 10-Q · filed 2016-05-03 | $99.77M derived: sum of 2 quarters · filed 2017-02-23 | $145.90M derived: sum of 3 quarters · filed 2017-02-23 | $188.35M derived: sum of 4 quarters · filed 2017-02-23 | ||||
| 2014-12-31 | $42.38M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $88.52M derived: sum of 2 quarters · filed 2017-02-23 | $130.96M derived: sum of 3 quarters · filed 2017-02-23 | $177.54M 10-K · filed 2017-02-23 | ||||
| 2014-09-30 | $46.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-30 | $88.58M derived: sum of 2 quarters · filed 2015-10-30 | $135.16M 10-Q · filed 2015-10-30 | $158.53M derived: sum of 4 quarters · filed 2016-02-16 | ||||
| 2014-06-30 | $42.44M 10-Q · filed 2014-07-31 | $89.02M 10-Q · filed 2015-08-04 | $112.39M derived: sum of 3 quarters · filed 2016-02-16 | $143.70M derived: sum of 4 quarters · filed 2016-02-16 | ||||
| 2014-03-31 | $46.58M 10-Q · filed 2015-05-04 | $69.95M derived: sum of 2 quarters · filed 2016-02-16 | $101.26M derived: sum of 3 quarters · filed 2016-02-16 | $142.61M derived: sum of 4 quarters · filed 2016-02-16 | ||||
| 2013-12-31 | $23.37M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-16 | $54.68M derived: sum of 2 quarters · filed 2016-02-16 | $96.03M derived: sum of 3 quarters · filed 2016-02-16 | $127.30M 10-K · filed 2016-02-16 | ||||
| 2013-09-30 | $31.31M 10-Q · filed 2013-11-07 | $72.66M derived: sum of 2 quarters · filed 2014-07-31 | $103.93M 10-Q · filed 2014-11-06 | $131.57M derived: sum of 4 quarters · filed 2015-02-13 | ||||
| 2013-06-30 | $41.35M 10-Q · filed 2014-07-31 | $72.63M 10-Q · filed 2014-07-31 | $100.26M derived: sum of 3 quarters · filed 2015-02-13 | $127.84M derived: sum of 4 quarters · filed 2015-02-13 | ||||
| 2013-03-31 | $31.27M 10-Q · filed 2014-05-05 | $58.91M derived: sum of 2 quarters · filed 2015-02-13 | $86.49M derived: sum of 3 quarters · filed 2015-02-13 | $117.87M derived: sum of 4 quarters · filed 2015-02-13 | ||||
| 2012-12-31 | $27.64M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | $55.22M derived: sum of 2 quarters · filed 2015-02-13 | $86.60M derived: sum of 3 quarters · filed 2015-02-13 | $114.28M 10-K · filed 2015-02-13 | ||||
| 2012-09-30 | $27.58M 10-Q · filed 2013-11-07 | $58.96M derived: sum of 2 quarters · filed 2013-11-07 | $86.65M 10-Q · filed 2013-11-07 | $115.70M derived: sum of 4 quarters · filed 2014-02-11 | ||||
| 2012-06-30 | $31.38M 10-Q · filed 2013-08-02 | $59.07M 10-Q · filed 2013-08-02 | $88.12M derived: sum of 3 quarters · filed 2014-02-11 | $117.53M derived: sum of 4 quarters · filed 2014-02-11 | ||||
| 2012-03-31 | $27.69M 10-Q · filed 2013-05-08 | $56.74M derived: sum of 2 quarters · filed 2014-02-11 | $86.16M derived: sum of 3 quarters · filed 2014-02-11 | $118.03M derived: sum of 4 quarters · filed 2014-02-11 | ||||
| 2011-12-31 | $29.05M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-11 | $58.47M derived: sum of 2 quarters · filed 2014-02-11 | $90.35M derived: sum of 3 quarters · filed 2014-02-11 | $118.23M 10-K · filed 2014-02-11 | ||||
| 2011-09-30 | $29.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $61.29M derived: sum of 2 quarters · filed 2012-11-06 | $89.17M 10-Q · filed 2012-11-06 | $112.75M derived: sum of 4 quarters · filed 2013-03-01 | ||||
| 2011-06-30 | $31.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | $59.76M 10-Q · filed 2012-08-08 | $83.33M derived: sum of 3 quarters · filed 2013-03-01 | $107.10M derived: sum of 4 quarters · filed 2013-03-01 | ||||
| 2011-03-31 | $27.88M 10-Q · filed 2012-05-10 | $51.45M derived: sum of 2 quarters · filed 2013-03-01 | $75.22M derived: sum of 3 quarters · filed 2013-03-01 | $99.67M derived: sum of 4 quarters · filed 2013-03-01 | ||||
| 2010-12-31 | $23.57M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | $47.34M derived: sum of 2 quarters · filed 2013-03-01 | $71.79M derived: sum of 3 quarters · filed 2013-03-01 | $91.12M 10-K · filed 2013-03-01 | ||||
| 2010-09-30 | $23.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | $48.22M derived: sum of 2 quarters · filed 2011-11-03 | $67.55M 10-Q · filed 2011-11-03 | $85.28M derived: sum of 4 quarters · filed 2012-02-22 | ||||
| 2010-06-30 | $24.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-09 | $43.78M 10-Q · filed 2011-08-09 | $61.51M derived: sum of 3 quarters · filed 2012-02-22 | $81.64M derived: sum of 4 quarters · filed 2012-02-22 | ||||
| 2010-03-31 | $19.33M 10-Q · filed 2011-05-06 | $37.06M derived: sum of 2 quarters · filed 2012-02-22 | $57.19M derived: sum of 3 quarters · filed 2012-02-22 | $83.78M derived: sum of 4 quarters · filed 2012-02-22 | ||||
| 2009-12-31 | $17.73M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22 | $37.86M derived: sum of 2 quarters · filed 2012-02-22 | $64.44M derived: sum of 3 quarters · filed 2012-02-22 | $86.72M 10-K · filed 2012-02-22 | ||||
| 2009-09-30 | $20.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | $46.72M derived: sum of 2 quarters · filed 2010-10-28 | $69.00M 10-Q · filed 2010-10-28 | |||||
| 2009-06-30 | $26.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2010-08-03 | $48.86M 10-Q · filed 2010-08-03 | ||||||
| 2009-03-31 | $22.28M 10-Q · filed 2010-05-03 | |||||||
| 2008-12-31 | $57.98M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |